John Riedinger
Neurology · Bismarck, NDNPI 1205283546
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 24.3% of the total. 2025 is the largest year on record at $918, more than ten times the $16 reported in 2021.
Across 99 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$441
- AstraZeneca$165
- Biogen$135
- Novartis$106
- Bristol Myers Squibb$105
- Pfizer$88
- plus $772 from 25 others
What the payments were for
- Food & beverage$1,812100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $441 |
| AstraZeneca(2 entities) | 8 | $165 |
| Biogen | 7 | $135 |
| Novartis | 7 | $106 |
| Bristol Myers Squibb | 6 | $105 |
| Pfizer | 6 | $88 |
| Lundbeck LLC | 3 | $75 |
| Argenx US, Inc. | 3 | $53 |
| Grifols USA, LLC | 2 | $39 |
| Boston Scientific | 1 | $39 |
| Mallinckrodt Hospital Products Inc. | 2 | $36 |
| Acadia Pharmaceuticals Inc | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Johnson & Johnson | 2 | $34 |
| ANI Pharmaceuticals, Inc. | 2 | $34 |
| Octapharma USA, Inc. | 1 | $32 |
| UCB, Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Merz Pharmaceuticals, LLC | 1 | $31 |
| Sandoz | 1 | $29 |
| Piramal Critical Care | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Sanofi | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Catalyst Pharmaceuticals, Inc. | 1 | $23 |
| TG Therapeutics, Inc. | 1 | $22 |
| Springworks Therapeutics, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Ionis Pharmaceuticals, Inc. | 1 | $18 |
| Tanabe Pharma America, Inc. | 1 | $17 |
| Aurinia Pharma U.S., Inc. | 1 | $16 |
How this compares
$1,812 in reported general payments places this provider in the 75th percentile of 39 neurology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 21 | $36,290 |
| QuliptaAtogepant | 20 | $21,313 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $16,917 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 112 | $5,492 |
| Mycophenolate Mofetil | 22 | $2,871 |
| Pyridostigmine Bromide | 39 | $2,799 |
| Levetiracetam | 87 | $2,641 |
| Memantine Hcl | 22 | $1,920 |
| Gabapentin | 136 | $1,806 |
| Ropinirole ErRopinirole Hcl | 14 | $1,443 |
| Pregabalin | 41 | $1,165 |
| Lacosamide | 25 | $1,146 |
| Carbamazepine ErCarbamazepine | 13 | $1,121 |
| Tramadol Hcl ErTramadol Hcl | 11 | $839 |
| Donepezil Hcl | 71 | $835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta | $441 | $21,31320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 39 neurology providers in North Dakota.
Other neurology in Bismarck
- Jess MillerBismarck$2K
- Ralph DunniganBismarck$2K
- Berislav SpahijaBismarck$1K
- Jason DuchschererBismarck$773
- Stephanie MillerBismarck$621
- Chatree WongjiradBismarck$432
- Siriwan KriengkrairutBismarck$125
- Tanya HarlowFargo$73K
- Susan ScarberryFargo$67K
- Sarah KendroudFargo$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.